These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1602321)

  • 1. Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Turjanski N; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 May; 55(5):413. PubMed ID: 1602321
    [No Abstract]   [Full Text] [Related]  

  • 2. GABA agonist treatment improves tardive dyskinesia.
    Tamminga CA; Thaker GK; Ferraro TN; Hare TA
    Lancet; 1983 Jul; 2(8341):97-8. PubMed ID: 6134975
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
    Manson AJ; Iakovidou E; Lees AJ
    Mov Disord; 2000 Mar; 15(2):336-7. PubMed ID: 10752589
    [No Abstract]   [Full Text] [Related]  

  • 5. Gamma-vinyl GABA.
    Hammond EJ; Wilder BJ
    Gen Pharmacol; 1985; 16(5):441-7. PubMed ID: 2932363
    [No Abstract]   [Full Text] [Related]  

  • 6. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic trial of gamma-vinyl GABA, an inhibitor of GABA transaminase, in tardive dyskinesias induced by neuroleptics].
    Lambert PA; Cantiniaux P; Chabannes JP; Tell GP; Schechter PJ; Koch-Weser J
    Encephale; 1982; 8(3):371-6. PubMed ID: 6137357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias.
    Andersson U; Häggström JE
    Psychopharmacology (Berl); 1988; 94(3):298-301. PubMed ID: 2895937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 10. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
    Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-vinyl GABA: a new antiepileptic drug.
    Hammond EJ; Wilder BJ
    Clin Neuropharmacol; 1985; 8(1):1-12. PubMed ID: 3884148
    [No Abstract]   [Full Text] [Related]  

  • 12. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gamma-vinyl GABA in tardive dyskinesia.
    Korsgaard S; Casey DE; Gerlach J
    Psychiatry Res; 1983 Apr; 8(4):261-9. PubMed ID: 6136054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.
    Bennett JP; Landow ER; Schuh LA
    Neurology; 1993 Aug; 43(8):1551-5. PubMed ID: 8043043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
    Grant SM; Heel RC
    Drugs; 1991 Jun; 41(6):889-926. PubMed ID: 1715266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate release inhibition ineffective in levodopa-induced motor complications.
    Bara-Jimenez W; Dimitrova TD; Sherzai A; Aksu M; Chase TN
    Mov Disord; 2006 Sep; 21(9):1380-3. PubMed ID: 16758479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buspirone in the treatment of levodopa induced dyskinesias.
    Kleedorfer B; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):376-7. PubMed ID: 2056334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.